Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

Inclusion criteria

• Men and women with non-segmental vitiligo.
• ≥ 18 and <80 years.
• At least one pair bilateral of stable vitiligo lesions with a surface >2cm² and < 20cm², located outside the face unresponsive to medical treatment
• For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed.
• Affiliation to a social security system
• Signed informed consent
• Participants who agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.

Exclusion criteria

• Pregnant or breast-feeding women. Or women who plan to get pregnant during the study duration.
• Segmental or mixed vitiligo
• Vitiligo lesions located only on face, feet, or fingers. (dorsum of the hand accepted).
• Concomitant use of topical or systemic immunosuppressive medication or steroids
• Previous treatment with topical ruxolitinib cream or any systemic JAK inhibitor
• Areas that have already received surgical grafting
• Patients suffering from photodermatosis or taking photosensitive drugs
• Medical history of hypertrophic scars or keloids
• Medical history of skin cancer on the site to be treated
• Allergy to ruxolitinib cream, xylocaine or hyaluronic acid or trypsin (Viticell® must not be utilised with patients who are hypersensitive to hyaluronic acid or trypsin)
• Active infection
• Patients with thromboembolic risk
• Any dermatosis located on the treated site that could interfere with the evaluation of the treatment
• Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom
• Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
• Participants with active acute bacterial, fungal, or viral skin infection within 1 week before baseline;
• Participants with concurrent malignant disease or a history of that in the 5 years preceding the baseline visit except for adequately treated non metastatic malignancies;
• Participants with current and/or history of liver disease, including known hepatitis B or C, with hepatic or biliary abnormalities;
• Participants with current and/or history of tuberculosis;
• Participants who have used depigmentation treatments for past treatment of vitiligo or other pigmented areas.
• Patient under guardianship or curatorship